|Videos|July 24, 2016

What is Currently Being Done to Fight the Threats Associated with Antimicrobial-resistance?

Marion A. Kainer, MD, MPH, FRACP, FSHEA, director, Healthcare Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health, outlines currently available strategies to avoid antimicrobial resistance.

Marion A. Kainer, MD, MPH, FRACP, FSHEA, director, Healthcare Associated Infections and Antimicrobial Resistance Program, Tennessee Department of Health, outlines currently available strategies to avoid antimicrobial resistance.

Interview Transcript (slightly modified for readability)

“There is a lot of national momentum to fight antimicrobial resistance with the national action plan, to prevent antimicrobial resistance. The president signed an executive order to combat antimicrobial resistant bacteria. It focuses on preventing infections in the first place, making sure that we have appropriate use of antibiotics, that we ensure that this precious resource isn’t squandered.

The One Health Initiative [will help with] good surveillance, [by] understanding where we have antimicrobial-resistant organisms emerging, both in humans as well as on the farm. Ensuring that we have the appropriate diagnostics to be able to diagnose infections, and that we develop new therapeutic agents to treat infections which may become untreatable [is imperative]. International collaboration [is also important], because the United States is not an island. We have a lot of people who go overseas and then come back, and they may be colonized with multidrug-resistant organisms, such as [carbapenem-resistant Enterobacteriaceae].”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.